January 2010
Worldwide Biotech;Jan2010, Vol. 22 Issue 1, p1
Trade Publication
The article reports on the results from the talactoferrin randomized, double-blind, placebo-controlled Phase 2 trial in severe sepsis, conducted by Agennix AG. Results revealed that talactoferrin reduces the 28-day all-cause mortality from severe sepsis by 14.6%. According to Rajesh Malik, chief medical officer at Agennix, they are planning to promote talactoferrin for the indication.


Related Articles

  • Agennix Nosedives on Surprise Ph III Lung Cancer Drug Failure. Moran, Nuala // BioWorld Today;8/8/2012, Vol. 23 Issue 153, p1 

    The article reports on the failed results of Agennix AG's Phase III trial for its talactoferrin for lung cancer treatment. It notes that talactoferrin, the immune modulator, failed to improve overall survival when administered in addition to best supportive care in the placebo-controlled trial...

  • Agennix Finishes Recruitment for NSCLC Drug's Phase III. Moran, Nuala // BioWorld International;3/23/2011, Vol. 16 Issue 12, p1 

    The article reports that AgenniX AG has completed recruitment for the Phase III trial of talactoferrin, a drug being developed for non-small-cell lung cancer (NSCLC). The Munich, Germany-based company is also preparing a Phase IIb trial of the drug for sepsis. Chief medical officer Rajesh Malik...

  • Drug approval in Europe. Walsh, Gary // Nature Biotechnology;Mar1999, Vol. 17 Issue 3, p237 

    The EMEA gets good grades, but has room for improvement.

  • WEEK IN REVIEW.  // BioWorld Insight;1/24/2011, Vol. 19 Issue 4, p5 

    The article offers news briefs in the U.S. related to the drug development industry which include the 7.1 million U.S. dollar increase in public offering at Ardea Biosciences Inc., the acquisition of Amgen Inc.'s manufacturing facility in Fremont, California by Boehringer Ingelheim GmbH, the...

  • No quick drug cure expected for obesity. Wei Yu // Michigan Citizen;4/15/2012, Vol. 34 Issue 23, pA9 

    The article reports on the approach of federal advisers to Qnexa and Lorcaserin to undergo clinical trials for their two new obesity drugs which are awaiting approval from the U.S. Food and Drug Administration.

  • Patient-Level Data Provide Additional Insight for Tigecycline All-Cause Mortality Meta-analysis. McGovern, Paul C.; Quintana, Alvaro // Clinical Infectious Diseases;Dec2012, Vol. 55 Issue 12, p1739 

    A letter to the editor is presented in response to the article "Excess deaths associated with tigecycline after approval based on non-inferiority trials," published in a previous issue of the periodical.

  • Too few patients are studied for long-term-use drug approvals.  // Reactions Weekly;03/23/2013, Issue 1445, p2 

    The article reports that according to the results of a database analysis of all new drugs approved in the European Union (EU) during 2000-2010, all chronic-use drugs were not evaluated in enough patients before their approval.

  • Agennix Nosedives on Surprise Ph III Lung Cancer Drug Failure. Moran, Nuala // BioWorld International;8/8/2012, Vol. 17 Issue 32, p1 

    The article reports on the failure of Agennix AG's lead product talactoferrin to pass the Phase III trial in lung cancer. It notes that the efficacy of the company's immune modulator was not observed in the placebo-controlled trial involving patients with advanced non-small-cell lung cancer, who...

  • Clinic Roundup.  // BioWorld Today;10/12/2011, Vol. 22 Issue 198, p8 

    This section offers news briefs on biotechnology research as of October 12, 2011. Acton Pharmaceuticals Inc. presented Phase IIIb results about its Aerospan inhalation aerosol. Agennix AG released data from a Phase II study of oral immunotherapy talactoferrin. Boston Therapeutics Inc. launched...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics